Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/10213
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRadosavljevic, Gordana-
dc.contributor.authorLjujic, Biljana-
dc.contributor.authorJovanovic I.-
dc.contributor.authorSrzentic Z.-
dc.contributor.authorPavlovic G.-
dc.contributor.authorZdravkovic, Nemanja-
dc.contributor.authorMilovanovic, Marija-
dc.contributor.authorBanković D.-
dc.contributor.authorKnezevic M.-
dc.contributor.authorAćimović L.-
dc.contributor.authorArsenijevic, Nebojsa-
dc.date.accessioned2021-04-20T15:10:13Z-
dc.date.available2021-04-20T15:10:13Z-
dc.date.issued2010-01-01-
dc.identifier.issn00282685-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/10213-
dc.description.abstractThe promotion of tumor growth is due to a combination of several mechanisms, including angiogenesis and the abundance of cell-derived inflammatory cytokines. The aim of this study was to investigate the serum levels of interleukin 17 (IL-17) and the expression of p53 and Vascular Endothelial Growth Factor (VEGF), in order to determine the relationship between these markers and serum IL-17 levels in patients with colorectal carcinoma. Serum levels of the proinflammatory cytokine IL-17 in patients with colorectal carcinoma (CRC) (n=40) and in a healthy group (n=37) were analysed by ELISA. Surgically resected specimens of 59 colorectal carcinomas were studied by immunohistochemical staining for VEGF and p53. Analyses by ELISA showed significantly higher IL-17 serum levels in patients with colorectal carcinoma than in control subjects (IL-17; mean 128.52±47.62 pg/ml vs. mean 101.91±22.46 pg/ml; p=0.022). We also found an inverse correlation between p53 expression and the level of IL-17 in the serum of patients with CRC. In fact, the serum concentration of IL-17 was significantly higher in patients who did not express p53 (p=0.023). There was no significant correlation between the expression of p53 and VEGF. However, concomitant expression of VEGF and p53 showed a significant correlation with the histological and nuclear grade of the carcinoma. The data presented in our study indicate that IL-17 might act as a valuable tumor marker in patients with CRC and that combined analysis of p53 and VEGF expression might provide additional information about tumor features.-
dc.relation.ispartofNeoplasma-
dc.titleInterleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma-
dc.typearticle-
dc.identifier.doi10.4149/neo_2010_02_135-
dc.identifier.scopus77953628124-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

112

Downloads(s)

7

Files in This Item:
File Description SizeFormat 
10.4149-neo_2010_02_135.pdf2.53 MBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.